title: Effects of fructans-type prebiotics on lipid metabolism.
abstract: Several nondigestible but fermentable dietary carbohydrates are able to regulate lipemia and triglyceridemia in both humans and animals. The mechanism of their serum lipid-lowering effect remains to be elucidated. Oligofructose, which is a mixture of nondigestible and fermentable fructans, can decrease triacylglycerol in VLDL when given to rats. The triacylglycerol-lowering action of oligofructose is due to a reduction of de novo fatty acid synthesis in the liver through inhibition of all lipogenic enzymes, namely acetyl-CoA carboxylase (EC 6.4.1.2), fatty acid synthase, malic enzyme (EC 1.1.1.40), ATP citrate lyase (EC 4.1.3.8), and glucose-6-phosphate dehydrogenase (EC 1.1.1.49). Our results suggest that oligofructose decreases lipogenic enzyme gene expression. Postprandial insulin and glucose concentrations are low in the serum of oligofructose-fed animals and this could explain, at least partially, the metabolic effect of oligofructose. Moreover, some events occurring in the gastrointestinal tract after oligofructose feeding could be involved in the antilipogenic effect of this fructan: the production of propionate through fermentation, a modulation of the intestinal production of incretins (namely glucose-dependent insulinotropic peptide and glucagon-like peptide-1), or the modification of the availability of digestible carbohydrates. Recent studies showed that the hypotriglyceridemic effect of fructans also occurs in humans.
authors.affiliation: UCL-Université catholique de Louvain, School of Pharmacy, Brussels. delzenne@pmnt.ucl.ac.be
authors.forename: N M
authors.initials: NM
authors.lastname: Delzenne
authors.forename: N
authors.initials: N
authors.lastname: Kok
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D005227:Fatty Acids; D005630:Fructans / Q000008:administration & dosage / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D007328:Insulin; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000096:biosynthesis; D009844:Oligosaccharides / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000096:biosynthesis; D051381:Rats; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D005227:Fatty Acids; D005630:Fructans; D000960:Hypolipidemic Agents; D007328:Insulin; D008074:Lipoproteins; D018377:Neurotransmitter Agents; D009844:Oligosaccharides; D010446:Peptide Fragments; D014280:Triglycerides; C120489:oligofructose; C055453:glucagon-like peptide 1 (7-36)amide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon